Keryx Biopharmaceuticals announced positive final data from its Phase 3 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis.
Zyclara (imiquimod cream, Graceway Pharmaceuticals) has been approved for the treatment of external genital and perianal warts in patients ≥12 years of age.
Omthera Pharmaceuticals announced the initiation of its Phase 3 EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial evaluating Epanova for the treatment of patients with very high triglycerides.
Cytochroma announced initiation of its Phase 2b study of CTAP101 capsules for the treatment of patients with vitamin D insufficiency, secondary hyperparathyroidism (SHPT), and stage 3 CKD.
The CDC has updated its treatment guidelines for sexually transmitted diseases.
Ikaria announced the enrollment of the first patients in its Phase 3 study of Lucassin (terlipressin for injection) for the treatment of hepatorenal syndrome (HRS) Type 1.
Keryx announced results from its Phase 3 trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
Abbott announced results from its Phase 2 trial of atrasentan to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease).
Reata Pharmaceuticals and Abbott announced data from their Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.
Repros Therapeutics announced initiation of its Phase 2 study of Androxal (enclomiphene) for the treatment of type 2 diabetes in men with low testosterone.
